| 317 | 0 | 14 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：分析中重度代谢相关脂肪性肝病（MAFLD）发生的独立危险因素，构建中重度MAFLD危险因素的预测模型并验证其有效性。方法：第一部分，将2022年1～5月在海南医学院第二附属医院体检中心被确诊为MAFLD的278名体检者作为研究对象（训练集），收集人口学资料及化验指标，依据超声结果将其分为轻度MAFLD组（200人）和中重度MAFLD组（78人），单因素、多因素分析筛选独立危险因素。第二部分，运用二分类逻辑回归方程构建中重度MAFLD预测模型，列线图可视化呈现模型。第三部分，收集2022年11～12月我院体检中心被确诊为MAFLD的人群（外部验证集200人）作为中重度MAFLD预测模型的验证人群，分组同前。绘制代表模型区分度的受试者工作特征（receiver operating characteristic curve, ROC）曲线、校准曲线图和模型临床适用度评价模型效能等进行模型内外部验证。结果：中重度MAFLD的危险因素为空腹血糖（FPG）、血尿酸（UA）、甘油三脂（TG）、甘油三酯葡萄糖指数（TyG）、总胆固醇（CHOL）和高密度脂蛋白（HDL-C）。UA[OR=1.021, 95%CI (1.015, 1.027),P<0.001]和FPG[OR=1.575, 95%CI (1.158, 2.143),P=0.004]是中重度MAFLD人群的独立危险因素。可视化列线图模型显示UA是中重度MAFLD发生风险贡献较大的因素。ROC曲线显示训练集、内部验证集和外部验证集的AUC值分别为0.870 1、0.868 6和0.799 1；模型校准度校准后曲线几乎与参考线相重合，Hosmer-Lemeshow检验P>0.05；模型临床适用度绘制的决策曲线（decision curve analysis, DCA）高于两条极端曲线，预测中重度MAFLD患者能从预测模型中获益。结论：UA联合FPG构建的预测模型准确性较高、临床适用度较好，可应用于临床诊断。
Abstract：Objective: To analyze the independent risk factors for the occurrence of moderate-to-severe metabolic-associated fatty liver disease(MAFLD), to construct a prediction model for moderate-to-severe MAFLD, and to verify the validity of the model. Methods: In the first part, 278 medical examiners who were diagnosed with MAFLD in Medical Examination Center at the Second Affiliated Hospital of Hainan University from January to May 2022 were taken as the study subjects(training set), and they were divided into mild MAFLD group(200) and moderate-severe MAFLD group(78) based on ultrasound results. Demographic data and laboratory indexes were collected, and risk factors were screened by univariate and multifactor analysis. In the second part, a dichotomous logistic regression equation was used to construct a prediction model for moderate-to-severe MAFLD, and the model was visualized in a line graph. In the third part, the MAFLD population(200 people in the external validation set) from our physical examination center from November to December 2022 was collected as the moderate-to-severe MAFLD prediction model, and the risk factors in both groups were compared. The receiver operating characteristic(ROC) curves, calibration curves, and clinical applicability of the model were plotted to represent model discrimination for internal and external validation. Results: The risk factors of moderate-to-severe MAFLD were fasting glucose(FPG), blood uric acid(UA), triglycerides(TG), triglyceride glucose index(TyG), total cholesterol(CHOL), and high-density lipoprotein(HDL-C). UA [OR=1.021, 95% CI(1.015, 1.027), P<0.001] and FPG [OR=1.575, 95% CI(1.158, 2.143), P=0.004] were independent risk factors for people with moderate to severe MAFLD. The visualized line graph model showed that UA was the factor contributing more to the risk of moderate to severe MAFLD in this model. The ROC curves showed AUC values of 0.870 1, 0.868 6 and 0.799 1 for the training set, internal validation set and external validation set, respectively. The curves almost coincided with the reference line after calibration of the model calibration degree with P>0.05 in Hosmer-Lemeshow test.The decision curve analysis(DCA) plotted by the clinical applicability of the model was higher than the two extreme curves, predicting that patients with moderate to severe MAFLD would benefit from the prediction model. Conclusion: The prediction model constructed by combining FPG with UA has higher accuracy and better clinical applicability, and can be used for clinical diagnosis.
1 Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J].JHepatol,2020,73(1):202-209.
2 Wang X,Wu S,Yuan X,et al.Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults:A prospective cohort study[J].JClin Endocrinol Metab,2022,107(2):e745-e755.
3 Wang QX,Xue J,Shi MJ,et al.Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-Aretrospective cohort study[J].Diabetes Metab Syndr Obes,2022,15:2311-2322.
4 Rivera-Aguirre J,Nahúm López-Sánchez G,Carlos Chávez-Tapia N,et al.Metabolic-associated fatty liver disease regulation through nutri epigenetic methylation[J].Mini Rev Med Chem,2023.
5 Lim GEH,Tang A,Ng CH,et al.An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD[J].Clin Gastroenterol Hepatol,2021,21(3):619-629,e7.
6 Ayada I,van Kleef LA,Alferink LJM,et al.Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis:Focusing on the non-overlap groups[J].Liver Int,2022,42:277-287.
7 Wong VW,Wong GL,Woo J,et al.Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J].Clin Gastroenterol Hepatol,2021,19:2161-2171.
8 Chen YL,Li H,Li S,et al.Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China:A cross-sectional comparative study[J].BMC Gastroenterol,2021.21:212.
9 Fouad Y,Esmat G,Elwakil R,et al.The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J].Saudi JGastroenterol,2022,28(1):3-20.
10 Shao CX,Ye J,Dong Z,et al.Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease[J].Ther Adv Chronic Dis,2021.12:20406223211033119.
11 Ye J,Zhuang X,Li X,et al.Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease:A data-driven cluster analysis with international validation[J].Metabolism,2022,136:155294.
12 Powell EE,Wong VW,Rinella M.Non-alcoholic fatty liver disease[J].Lancet,2021,397(10290):2212-2224.
13姜一农.高血压伴无症状高尿酸血症管理中国专家共识[J].中华高血压杂志，2022,30(11):1014-1019.
14 Zheng J,Li X,Zhang Y,et al.Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population[J].J Transl Med,2023,21(1):39.
15 Shen HC,Zhao ZH,Hu YC,et al.Relationship between obesity,metabolic syndrome,and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan[J].Clin Interv Aging,2014,9:501-508.
16 Petta S,CammàC,Cabibi D,et al.Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2011,34(7):757-766.
17 Wei F,Li J,Chen C,et al.Higher serum uric acid level predicts non-alcoholic fatty liver disease:A 4-year prospective cohort study[J].Front Endocrinol (Lausanne),2020,11:179.
18 Wan X,Xu C,Lin Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.
19 Xu C,Yu C,Ma H,et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:The Zhejiang Zhenhai Study[J].Am J Gastroenterol,2013,108(8):1299-1304.
20 Copur S,Demiray A,Kanbay M.Uric acid in metabolic syndrome:Does uric acid have a definitive role?[J].Eur J Intern Med,2022,103:4-12.
21徐琦，赵冬晖，张玲玲，等.中青年人群血尿酸水平与非酒精性脂肪性肝病及颈动脉粥样硬化的相关性[J].实用临床医药杂志，2022,26(10):20-25.
22 He J,Ye J,Sun Y,et al.The additive values of the classification of higher serum uric acid levels as a diagnostic criteria for metabolic-associated fatty liver disease[J].Nutrients,2022,14(17):3587.
23 Xie D,Zhao H,Lu J,et al.High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling[J].Am JPhysiol Endocrinol Metab,2021,320(6):E1032-E1043.
24 Evans JL,Maddux BA,Goldfine ID.The molecular basis for oxidative stress-induced insulin resistance[J].Antioxid Redox Signal,2005,7(7-8):1040-1052.
25 Sautin YY,Nakagawa T,Zharikov S,et al.Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress[J].Am J Physiol Cell Physiol,2007,293(2):C584-C596.
26 Wan X,Xu C,Lin Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.
27 Xie D,Zhao H,Lu J,et al.High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling[J].Am JPhysiol Endocrinol Metab,2021,320(6):E1032-E1043.
28 Muriel P,Lopez-Sanchez P,Ramos-Tovar E.Fructose and the Liver[J].Int J Mol Sci,2021,22(13):6969.
29 Jensen T,Abdelmalek MF,Sullivan S,et al.Fructose and sugar:A major mediator of non-alcoholic fatty liver disease[J].J Hepatol,2018,68(5):1063-1075.
30 Thuy S,Ladurner R,Volynets V,et al.Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1concentrations and with fructose intake[J].J Nutr,2008,138(8):1452-1455.
31 Cheng KC,Lin YM,Liu CC,et al.High red cell distribution width is associated with worse prognosis in early colorectal cancer after curative resection:A propensity-matched analysis[J].Cancers (Basel),2022,14(4):945.
32 Xanthopoulos A,Tryposkiadis K,Dimos A,et al.Red blood cell distribution width in elderly hospitalized patients with cardiovascular disease[J].World J Cardiol,2021,13:503-513.
33 Chen M,Liao L,Yan J,et al.Predictive value of red blood cell distribution width for 1-year all-cause mortality in critically ill patients with acute myocardial infarction[J].Int J Gen Med,2022,15:465-471.
34 Moreno C,Mueller S,Szabo G.Non-invasive diagnosis and biomarkers in alcohol-related liver disease[J].J Hepatol,2019,70:273-283.
35 Hsu C,Caussy C,Imajo K,et al.Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease:A systematic review and pooled analysis of individual participants[J].Clin Gastroenterol Hepatol,2019,17:630-637.e8.
36 Michalak A,Guz M,Kozicka J,et al.Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease[J].World J Gastroenterol,2022,28(38):5636-5647.
基本信息:
DOI：10.13210/j.cnki.jhmu.20230324.001
中图分类号:R575.5
引用信息:
[1]张大涯,陈世锔,陈润祥,等.代谢相关脂肪性肝病的严重程度预测模型构建与验证[J].海南医学院学报,2023,29(08):581-587.DOI:10.13210/j.cnki.jhmu.20230324.001.
基金信息:
海南省临床医学中心建设项目资助（2021818）; 海南省院士团队创新中心建设项目资助（2022136）; 海南省院士创新平台科研项目资金资助（00817378）; 海南省卫生健康行业科研项目资助（22A200078）; 海南省研究生创新科研课题（Qhyb2022-133）~~
2023-03-26
2023-03-26
2023-03-26